WASHINGTON—Today, AARP CEO Dr. Myechia Minter-Jordan issued the following statement in response to the Centers for Medicare & Medicaid Services (CMS) announcement of the second round of Medicare-negotiated drug prices due to the 2022 prescription drug law: 

“Today’s announcement marks yet another significant next step forward in our long-standing efforts to lower prescription drug prices. Older Americans across the political spectrum consistently say lower drug prices are a top priority, and these negotiated prices will bring meaningful relief to millions of people on Medicare. Our members are eager to see the first round of lower prescription drug prices take effect on January 1, 2026, and we thank the Administration for ensuring Medicare's ability to negotiate lower drug prices is protected so older Americans benefit for decades to come. As the voice for 125 million Americans 50-plus, AARP will keep fighting to make prescription drugs more affordable.” 

###

AARP is the nation's largest nonprofit, nonpartisan organization dedicated to empowering people 50 and older to choose how they live as they age. With a nationwide presence, AARP strengthens communities and advocates for what matters most to the 125 million Americans 50-plus and their families: health and financial security, and personal fulfillment. AARP also produces the nation's largest-circulation publications: AARP The Magazine and AARP Bulletin. To learn more, visit www.aarp.org/about-aarp/, www.aarp.org/español or follow @AARP, @AARPLatino and @AARPadvocates on social media.